Bill Malcolm
About Bill Malcolm
Bill Malcolm is the Senior Director of Worldwide HEOR Economic & Predictive Modelling at Bristol Myers Squibb in the United Kingdom, with extensive experience in health economics, outcomes research, and medical education.
Title and Current Role
Bill Malcolm is currently the Senior Director Worldwide HEOR Economic & Predictive Modelling at Bristol Myers Squibb in the United Kingdom. He holds a significant leadership position where he oversees global health economics and outcomes research, focusing on economic and predictive modelling initiatives.
Career at Bristol Myers Squibb
Bill Malcolm has held numerous positions at Bristol Myers Squibb. Prior to his current role, he was the Group Director WWHEOR Economic & Predictive Modelling CAR-T/HAEM for 9 months from 2020 to 2021. From 2017 to 2020, he served as the Director Worldwide HEOR, Tumour Lead, Immuno-Oncology, based in London, UK. His tenure at Bristol Myers Squibb began in 2015 as Associate Director Worldwide HEOR - Immuno-oncology in Uxbridge, UK. In each of these roles, he was instrumental in driving the company's health economics and outcomes research efforts.
Experience at Novartis
Before his time at Bristol Myers Squibb, Bill Malcolm worked at Novartis in various capacities. In 2015, he was the Global HEOR Director (split role) for 8 months in Basel Area, Switzerland. From 2012 to 2015, he was the Senior Health Economics & Outcomes Research Manager (split role) in Frimley, Surrey, UK. Prior to that, he was the Senior Medical Development Advisor at Novartis UK from 2010 to 2012. Throughout his roles, he continually advanced Novartis’ health economics and outcomes research objectives.
Career at AstraZeneca
Bill Malcolm's professional journey includes a significant tenure at AstraZeneca as a Medical Scientific Liaison, a role he held from 2006 to 2010. His work involved engaging with key opinion leaders, designing clinical trials, and facilitating the scientific and medical communication of AstraZeneca's clinical research.
Education and Academic Qualifications
Bill Malcolm holds a Master's degree in Health Economics and Health Policy from The University of Birmingham, which he pursued from 2009 to 2012. Additionally, he earned a BSc (Hons) in Biological and Biomedical Sciences from Sheffield University, completed between 1998 and 2001. His academic background has equipped him with a strong foundation in health economics and biological sciences.
Research and Contributions
Bill Malcolm has contributed to the field of health economics through published research, particularly in new methods in Bayesian Network Meta-analysis. He has significant experience in real-world effectiveness studies and has developed medical education programs focused on evidence-based medicine and statistics. Additionally, he has served as an industry representative for ABPI AWMSG.
KOL Development and Training
Bill Malcolm has comprehensive experience in Key Opinion Leader (KOL) development and clinical trials feasibility and design. He has also worked as a scientific signatory, providing training for promotional organizations. His ability to supervise, train, and mentor new sales professionals, including managing ITCs and conducting in-field coaching, underscores his leadership and expertise in the pharmaceutical industry.